기복기 시장 : 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

Insufflation devices market size in 2026 is estimated at USD 3.28 billion, growing from 2025 value of USD 3.10 billion with 2031 projections showing USD 4.37 billion, growing at 5.88% CAGR over 2026-2031.

Rising volumes of minimally invasive procedures, stronger evidence of quicker patient recovery, and payer pressure for total-episode cost reductions are accelerating demand. Rapid integration of insufflation systems with robotic platforms, the rollout of FDA guidance for AI-enabled surgical software, and the shift of complex cases into ambulatory settings are sharpening competitive differentiation. North American providers continue to refresh installed bases for performance-linked contracts, whereas emerging Asian hospitals prioritize first-time purchases of affordable systems. Together, these forces are setting a higher performance bar and widening the technology adoption gap between early and late movers.

Global Insufflation Devices Market Trends and Insights

Rising Prevalence of Minimally-Invasive Surgeries

Minimally invasive techniques now dominate gallbladder removal, colorectal resection and thoracic interventions, pushing the medical insufflation systems market toward reliable, high-flow technology. Laparoscopic approaches already exceed 96% of cholecystectomies and increasingly replace open procedures in bariatric and gynecologic oncology practices. Medicare data show 3.4 million ASC beneficiaries in 2023, underscoring outpatient migration where insufflation enables same-day discharge. Enhanced Recovery After Surgery (ERAS) pathways rely on heated, humidified gas to preserve core temperature and accelerate bowel function. Collectively, these shifts keep demand for insufflators on an upward trajectory within the medical insufflation systems market.

Technological Advances in Flow-Controlled & Heated-Humidified Insufflators

Heated-humidified insufflators maintain core temperature, cut postoperative shivering and prevent hypothermia, driving premium adoption in the medical insufflation systems market. Systems such as AirSeal sustain pneumoperitoneum at low pressure, curtailing subcutaneous emphysema while filtering surgical smoke. Stryker's PneumoClear couples 50 L/min flow with particulate removal down to 0.051 microns, improving visibility in robotic and standard laparoscopy. Embedded sensors automatically modulate flow in real time, marking a shift from passive to smart insufflation. These innovations widen clinical indications and reinforce the competitive edge of vendors in the medical insufflation systems market.

Expansion of Ambulatory Surgical Centers

Roughly 6,300 U.S. ASCs performed 5.7% more procedures per beneficiary in 2023, channeling USD 6.8 billion in Medicare spending. ASC cost advantages over hospital outpatient departments attract payers and patients, heightening the call for portable, rapid-setup insufflators. Smoke-evacuation laws now enforced in 26 states mandate integrated filtration, accelerating equipment refresh cycles ascfocus.org. The convergence of legislative pressure and volume growth positions ASCs as a strategic demand hub for the medical insufflation systems market.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Adoption in Bariatric & Gynecologic Procedures
2. Post-operative CO2-Related Complications
3. High Capital Cost of Advanced Units

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Insufflation systems anchor surgical suites, delivering 72.12% revenue in 2025 as hospitals standardize on network-ready consoles that integrate with OR information systems. The sizeable installed base underpins long-term service contracts and periodic software upgrades that lift recurring revenue streams. In contrast, accessories such as single-use tubing, filters, and valves are registering a 6.98% CAGR, propelled by infection-control guidelines that favor disposables. The insufflation devices market size for accessories is projected to rise in lockstep with procedure volumes, creating a lucrative annuity stream for vendors bundling consumables with capital units.

Hospitals in North America and Europe increasingly negotiate value-based packages, exchanging higher console prices for guaranteed consumable supply deals. Meanwhile, manufacturers embed pressure sensors and RFID chips into tubing sets, enabling auto-calibration and stock tracking that streamline supply-chain workflows. These smart disposables support premium pricing, cushioning margin pressure from cost-sensitive buyers in emerging economies and keeping the insufflation devices market on a robust growth trajectory.

The Insufflation Devices Market Report is Segmented by Product Type (Insufflation Systems, Disposable Tubing & Accessories), Application (Laparoscopic Surgery, Bariatric Surgery, Gynecological Surgery, Cardiac Surgery, Other Surgeries), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics & Others), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America commanded 38.20% of global revenue in 2025, anchored by robust capital budgets, rapid robotic uptake, and a supportive reimbursement framework that rewards shorter stays. U.S. regulators issued 2025 draft guidance for AI-enabled surgical software, encouraging manufacturers to embed analytics and predictive algorithms in next-gen insufflators. Canadian health systems are earmarking funds to refresh aging laparoscopic stacks, while Mexico's private hospital groups co-invest with suppliers via long-term service agreements to manage cash flow.

Europe maintains stable growth as national health services pursue operating-room efficiency programs. Germany's 97% laparoscopic appendectomy standard demonstrates entrenched MIS culture, while the European Association for Endoscopic Surgery's post-COVID guidelines accelerate protocol harmonization. Southern European markets use EU recovery funds to upgrade OR ventilation and smoke evacuation systems, often bundling insufficient pumps in turnkey packages.

Asia-Pacific leads on momentum with a 8.92% CAGR. China's expedited device approvals and expanded volume-based procurement have opened doors for both multinationals and local innovators. India's shortage of 13.5 surgical specialists per 100,000 citizens fuels public-private partnerships to establish treatment hubs that require scalable MIS infrastructure. Japan and South Korea, already robotic heavyweights, are piloting AI-enhanced insufflators that integrate with 8K arthroscopes.

South America, the Middle East, and Africa offer selective upside. Brazilian reference centers buy top-tier consoles, whereas broader adoption is hamstrung by training deficits and currency volatility. Gulf Cooperation Council nations incorporate insufflation capacity in greenfield hospital projects, leveraging petrodollar budgets to acquire full robotic suites. Sub-Saharan initiatives lean toward gasless technology to overcome CO2 logistic hurdles, providing low-cost entry lanes for frugal innovators.

1. Karl Storz
2. Stryker
3. Richard Wolf
4. Johnson & Johnson
5. Olympus
6. Medtronic
7. Conmed
8. Smiths Group
9. B. Braun
10. Teleflex
11. Applied Medical Resources
12. W.O.M. World of Medicine GmbH
13. Bracco
14. Fujifilm Holdings Corp.
15. Hoya Corp. (Pentax Medical)
16. Steris plc
17. Alesi Surgical Ltd. (Insuflow)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising prevalence of minimally-invasive surgeries
  • 4.2.2 Technological advances in flow-controlled & heated-humidified insufflators
  • 4.2.3 Growing adoption in bariatric & gynecologic procedures
  • 4.2.4 Expansion of ambulatory surgical centers
  • 4.2.5 Integration with next-generation robotic platforms
  • 4.2.6 Shift toward single-use insufflation tubing to curb cross-contamination
• 4.3 Market Restraints
  • 4.3.1 Post-operative CO2-related complications (e.g., hypercapnia)
  • 4.3.2 High capital cost of advanced units
  • 4.3.3 Shortage of skilled laparoscopic surgeons in emerging markets
  • 4.3.4 Environmental regulations constraining medical-grade CO2 supply
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Product Type
  • 5.1.1 Insufflation Systems
  • 5.1.2 Disposable Tubing & Accessories
• 5.2 By Application
  • 5.2.1 Laparoscopic Surgery
  • 5.2.2 Bariatric Surgery
  • 5.2.3 Gynecological Surgery
  • 5.2.4 Cardiac Surgery
  • 5.2.5 Other Surgeries
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Ambulatory Surgical Centers
  • 5.3.3 Specialty Clinics & Others
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 India
    • 5.4.3.3 Japan
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 South America
    • 5.4.4.1 Brazil
    • 5.4.4.2 Argentina
    • 5.4.4.3 Rest of South America
  • 5.4.5 Middle East and Africa
    • 5.4.5.1 GCC
    • 5.4.5.2 South Africa
    • 5.4.5.3 Rest of Middle East and Africa

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Karl Storz SE & Co. KG
  • 6.3.2 Stryker Corporation
  • 6.3.3 Richard Wolf GmbH
  • 6.3.4 Johnson & Johnson (Ethicon)
  • 6.3.5 Olympus Corporation
  • 6.3.6 Medtronic plc
  • 6.3.7 CONMED Corporation
  • 6.3.8 Smith & Nephew plc
  • 6.3.9 B. Braun Melsungen AG
  • 6.3.10 Teleflex Incorporated
  • 6.3.11 Applied Medical Resources
  • 6.3.12 W.O.M. World of Medicine GmbH
  • 6.3.13 Bracco Diagnostics Inc.
  • 6.3.14 Fujifilm Holdings Corp.
  • 6.3.15 Hoya Corp. (Pentax Medical)
  • 6.3.16 Steris plc
  • 6.3.17 Alesi Surgical Ltd. (Insuflow)

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment